Curis Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907

[at noodls] – LEXINGTON, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, … more

View todays social media effects on CRIS

View the latest stocks trending across Twitter. Click to view dashboard

See who Curis is hiring next, click here to view